The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
The UK company insists that by the end of the year a partner will have been found for its microbiome project to prevent C difficile infections.
The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
The average takeout premium for a research-stage biotech is tracking at 100% this year, the latest data show.